ALK and non-small cell lung carcinoma: The third-generation ALK-TKI, lorlatinib, was approved for ALK+ metastatic NSCLC with a recommended dosage of 100 mg once daily, based on a randomized, multicenter trial, Study B7461006 (NCT03052608) [106].